Clinical trials: Advanced Clear Cell Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Phase I / II, open, prospective, multicenter single-arm, Clinical Trial in two stages: in the first stage it will determine the optimal dose of the combination of pazopanib and interferon alfa-A2 in the treatment of patients with…
- Trial name
- NCT01513187
- Testing
- Pazopanib + interferon alpha 2A
- Where
- 13 sites in Spain
- Volunteers
- 53 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Carcinoma, Renal Cell
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
This study is an early access program of 'Nexavar post-marketing surveillance (PMS) for renal cell carcinoma (RCC) in Japan' which is a regulatory, local prospective and observational study for patients with unresectable or…
- Trial name
- NCT01412671
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 117 people
- Sponsor
- Bayer
Renal Cell Carcinoma
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.
- Trial name
- NCT03873402
- Testing
- Nivolumab, Ipilimumab
- Where
- 78 sites in United States, Argentina and 12 more
- Volunteers
- 437 people
- Sponsor
- Bristol-Myers Squibb
Advanced Renal Cell Carcinoma
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world…
- Trial name
- CaboCombo (NCT05361434)
- Where
- 66 sites in Belgium, France and 6 more
- Volunteers
- 311 people
- Sponsor
- Ipsen
Carcinoma, Renal Cell
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy.
- Trial name
- NCT07489495
- Testing
- Belzutifan, Zanzalintinib
- Where
- 106 sites in United States, Argentina and 17 more
- Volunteers
- 758 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Urothelial Carcinoma
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent
- Trial name
- NCT03827837
- Testing
- SHR-1210, Famitinib
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Advanced Cancer, Solid Tumors
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Primary Objective: -To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of SSG in combination with IFN alpha2b in patients with advanced malignancies.
- Trial name
- NCT00629200
- Testing
- Sodium Stibogluconate, Interferon Alpha-2b
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02771626
- Testing
- CB-839, Nivolumab
- Where
- 17 sites in United States
- Volunteers
- 118 people
- Sponsor
- Calithera Biosciences, Inc
Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
This phase I trial is studying the side effects and best way to give sunitinib malate in treating patients with unresectable or metastatic kidney cancer or other advanced solid tumors.
- Conditions
- Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer
- Trial name
- NCT00499135
- Testing
- Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Non-small-cell Lung Cancer
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or…
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT06285097
- Testing
- PF-07820435, Sasanlimab
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 9 people
- Sponsor
- Pfizer
Melanoma, Lung Cancer
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03050047
- Testing
- BCD-100
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
Kidney Neoplasms
EPO906 Therapy in Patients With Advanced Kidney Cancer
This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.
- Trial name
- NCT00035243
- Testing
- epothilone b
- Where
- 8 sites in United States, France
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Clear Cell Renal Cell Carcinoma
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum…
- Trial name
- NCT05433142
- Testing
- XmAb819
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 307 people
- Sponsor
- Xencor, Inc.
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumours
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain Fragment variable (scFv) format directed…
- Trial name
- NCT01058538
- Testing
- L19IL2
- Where
- 2 sites in Germany, Italy
- Volunteers
- 33 people
- Sponsor
- Philogen S.p.A.
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Metastatic Renal Cell Carcinoma
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab…
- Trial name
- NCT03075423
- Testing
- Ipilimumab plus nivolumab, Standard Therapy
- Where
- 30 sites in Belgium, Czechia and 5 more
- Volunteers
- 316 people
- Sponsor
- Goethe University
Locally Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Optimizing Pazopanib Exposure in RCC Patients
Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.
- Trial name
- OPERA (NCT02089802)
- Testing
- Pazopanib
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Carcinoma, Renal Cell
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
- Conditions
- Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Cell Renal Carcinoma
- Trial name
- MACS0460 (NCT00688753)
- Testing
- RAD001
- Where
- 19 sites in Belgium, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals